Dr. Mark W. Walberg, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 421
Licensed in Texas since 1994, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license J6272 (first issued 1994; voluntary charity care only)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 421
- Services billed
- 72,795
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 13,400 | 49 |
| Injection, fosaprepitant, 1 mg | 12,000 | 56 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 7,140 | 12 |
| Injection, paclitaxel, 1 mg | 6,517 | 31 |
| Injection, nivolumab, 1 mg | 5,940 | 11 |
| Injection, iron sucrose, 1 mg | 5,700 | 22 |
| Injection, oxaliplatin, 0.5 mg | 4,400 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,209 | 43 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 3,600 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,862 | 113 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 36 |
| Lenvima (lenvatinib mesylate) | 16 |
| Prochlorperazine Maleate Other prescribers in Dallas, TX | 16 |
| Prednisone Other prescribers in Dallas, TX | 12 |
| Sorafenib (sorafenib tosylate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $94.33 in total to this clinician.
| Janssen Scientific Affairs, LLC | $50.80 |
|---|---|
| Legend Biotech USA Inc. | $27.93 |
| AbbVie Inc. | $15.60 |
| Food and Beverage | $94.33 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.